24/7 Market News Snapshot 27 March, 2025 – Portage Biotech Inc. Common Stock (NASDAQ:PRTG)

March 27, 2025

DENVER, Colo., 27 March, 2025 (247marketnews.com) – (NASDAQ:PRTG) are discussed in this article.
Portage Biotech Inc. has experienced remarkable momentum, with its stock surging by over 105% to reach approximately $9.34 after opening at $4.40 today, underscoring strong investor confidence. This surge reflects heightened interest in the company’s innovative pipeline, with trading volume nearing 695.19K, suggesting continued robust market activity and potential for further increases.

In conjunction with the stock performance, Portage Biotech has made significant strides in its clinical research. At the European Lung Cancer Congress (ELCC) 2025, the company unveiled promising preclinical data for its candidate PORT-7, a selective Adenosine A2B receptor inhibitor. These results, presented by Dr. Luciano Mutti from the Gruppo Italiano Mesotelioma e Oncologia Ambientale, demonstrated remarkable single-agent efficacy. When combined with an anti-PD1 antibody, PORT-7 achieved over a 90% reduction in tumor growth in a murine model of mesothelioma, highlighting its potential as a transformative treatment for this aggressive cancer type.

Portage Biotech is gearing up to initiate a first-in-human clinical trial for PORT-7, further advancing its therapeutic pipeline. Additionally, the firm is developing PORT-6, another selective A2A receptor inhibitor, and plans to investigate the co-administration of both PORT-6 and PORT-7 in clinical trials. This comprehensive strategy aims to address adenosine-mediated immunosuppression and enhance the efficacy of immunotherapy in solid tumors.

As Portage Biotech continues to break new ground in cancer treatment, its commitment to innovative therapeutics is poised to contribute significantly to the ongoing battle against cancer. The company invites stakeholders to closely monitor its progress as it embarks on this promising journey.

Related news for (PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.